Disease overview: Multiple myeloma accounts for approximately 10% of hematologic
malignancies. Diagnosis: The diagnosis requires 10% or more clonal plasma cells on bone …

1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …

Combinations of bortezomib (V) and dexamethasone (D) with either lenalidomide (R) or
cyclophosphamide (C) have shown significant efficacy. This randomized phase 2 trial …

Background Bortezomib plus melphalan and prednisone (VMP) is significantly better than
melphalan plus prednisone alone for elderly patients with untreated multiple myeloma; …

In a recent phase 3 trial, bortezomib-melphalan-prednisone-thalidomide followed by
maintenance treatment with bortezomib-thalidomide demonstrated superior efficacy …

Purpose The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of
care for newly diagnosed multiple myeloma. This phase III study examined the efficacy of the …

Purpose In patients with myeloma, thalidomide significantly improves outcomes but
increases the risk of thromboembolic events. In this randomized, open-label, multicenter …

For establishing the true effect of different response categories in patients with multiple
myeloma (MM) treated with autologous stem cell transplantation, we evaluated, after a …

Disease overview: Multiple myeloma is malignant plasma‐cell disorder that accounts for∼∼
10% of all hematologic malignancies. Diagnosis: The diagnosis requires (1) 10% or more …

Disease overview: Multiple myeloma accounts for∼ 10% of all hematologic malignancies.
Diagnosis: The diagnosis requires 10% or more clonal plasma cells on bone marrow …